Michael Newman

Company: Indaptus Therapeutics

Job title: Founder & Chief Scientific Officer

Seminars:

Driving Pre-Clinical Anti-HBV Activity With a Novel Multi-TLR Agonist Therapeutic Vaccine 12:00 pm

• Ensuring safe induction of innate and adaptive immune pathways • Exploring the inhibition of plasma and liver viral DNA loads, as well as HBsAg and HBeAg • Discussing the potential safe synergy with standard of careRead more

day: Day Two